Arrhythmias, Cardiac, Implantable Defibrillator User, Ischemic Cardiomyopathy, Myocardial Infarction, Sudden Cardiac Death
Conditions
Keywords
Action potential duration restitution, Ventricular arrhythmia, Sudden cardiac death, Body-surface potential mapping, Electrocardiogram
Brief summary
It is universally recognised that current methods for risk stratification of sudden cardiac death (SCD) are limited. A novel SCD risk marker, the Regional Restitution Instability Index (R2I2), measures the degree of heterogeneity in electrical restitution using data obtained from a standard 12 lead ECG acquired during an invasive electrophysiological study. In an ischaemic cardiomyopathy (ICM) cohort of 66 patients, an R2I2 of ≥1.03 identified subjects with a significantly higher risk of ventricular arrhythmia (VA) or death (43%) compared with those with an R2I2 \<1.03 (11%) (P=0.004). This study will use non-invasive techniques to acquire electrical restitution data: exercise and pharmacological stress, and will incorporate body surface potential mapping to develop a non-invasive and high-resolution form of R2I2. Suitable patients will be recruited into a prospective, observational study. HYPOTHESES: PRIMARY: 1. R2I2 is predictive of ventricular arrhythmia (VA) / SCD in patients with ICM. 2. The exercise stress protocol will create a dynamic range of heart rates that allows ECG quantification of electrical restitution heterogeneity that correlates with invasive R2I2 and is predictive of VA/SCD. The pharmacological stress protocol will create a dynamic range of heart rates that allows ECG based quantification of electrical restitution heterogeneity that correlates with invasive R2I2 and is predictive of VA/SCD. SECONDARY: 1. A high-resolution electrical map acquired using body surface potential mapping will correlate with R2I2 and these data can be included in the R2I2 calculation to improve its prediction of SCD/VA. 2. Serial measurement of R2I2 will produce consistent values.
Interventions
None listed
Sponsors
Study design
Eligibility
Inclusion criteria
* Age \>18 * History of ischaemic cardiomyopathy
Exclusion criteria
* Unable to give informed consent * \<28 days since cardiac surgery or acute coronary syndrome
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ventricular arrhythmia/Sudden cardiac death | 18 months |
Secondary
| Measure | Time frame |
|---|---|
| Syncope | 18 months |
| All cause mortality | 18 months |
Countries
United Kingdom